





AWARDING AGREEMENT OF THE CONTRACT FOR THE SERVICE OF DNA AND RNA SEQUENCING AND SPECIALIZED BIOINFORMATIC ANALYSIS FROM TUMOR SAMPLES AND WHOLE BLOOD IN THE FUNDACIÓ HOSPITAL UNIVERSITARI VALL **HEBRON - INSTITUT DE RECERCA (VHIR).** 

Proyecto "PI23/01045", financiado por el Instituto de Salud Carlos III (ISCIII) y cofinanciado por la Unión Europea.




#### **2025-031 DNA AND RNA SEQUENCING (PI23/01045)**

In view of the minutes of the Contracting Committee for the opening of the proposals evaluated by applying formulas or automatic criteria, and the act of the justification of supposedly abnormal or disproportionate proposals in which the result and the consequent award proposal is recorded on 3<sup>rd</sup> of September of 2025 and on 29<sup>th</sup> of September of 2025, respectively, the following are the scores in descending order, in accordance with the different evaluation criteria established in the bidding documents:

SCORE BOARD							
				56%	14%	30%	
Offers submitted:	Economic Offer			Economic Offer	Automatic Evaluation criteria	Value Judgment	
	BI	VAT	TOTAL				TOTAL
Hartwig Medical	171.000,00	35.910,00€	206.910,00 €	36,02	14,00	30,00	80,02
Foundation	€ (*)						80,02
<b>Edinburgh Genetics</b>	110.000,00	23.100,00€	133.100,00€	56,00	11,00	21,25	EXCLUDED
Limited	€ (*)						
Sequentia Biotech							EXCLUDED
SL						-	EXCLUDED

<sup>(\*)</sup> Based on the unit prices quoted.

On 02<sup>nd</sup> October of 2025, the contracting body of the la Fundació Hospital Universitari Vall Hebron – Institut de Recerca (VHIR) requested to the company Hartwig Medical Foundation with NIF number NL855072490B01 the necessary documentation in order to raise the award of the contract of service of Next generation sequencing service and data analysis and report including DNA and RNA sequencing from human tumour samples, paired with sequencing of peripheral blood samples as a control sample by the Project PI23/01045 titled "Plataforma integrativa multiómica para la identificación de biomarcadores predictivos de respuesta a quimioterapia e inmunoterapia en cáncer de mama triple negativo temprano (PORTRAIT-TNBC)" of the Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR), funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. That likewise, the proposed company has accompanied within the deadline all the documentation required







for this purpose on 13<sup>th</sup> October of 2025, with the exception of the certificate from Caixa General de Dipòsits.

On 3<sup>rd</sup> November of 2025, the contracting body of the la Fundació Hospital Universitari Vall Hebron – Institut de Recerca (VHIR) requested the bidding company to submit the certificate from Caixa General de Dipòsits within three working days.

The proposed company submitted all the required documentation for this purpose on 3<sup>rd</sup> November of 2025.

And in use of the powers granted to me as contracting body by Fundació Hospital Universitari Vall Hebron – Institut de Recerca (VHIR) of Barcelona,

## RESOLVED,

**First.-** To elevate the award of the contract related to the service of Next generation sequencing service and data analysis and report including DNA and RNA sequencing from human tumour samples, paired with sequencing of peripheral blood samples as a control sample by the Project PI23/01045 titled "Plataforma integrativa multiómica para la identificación de biomarcadores predictivos de respuesta a quimioterapia e inmunoterapia en cáncer de mama triple negativo temprano (PORTRAIT-TNBC)" of the Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR), funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, to the following company:

#### a) Successful bidder:

- a. Company name: Hartwig Medical Foundation
- b. NIF: NL855072490B01
- c. Registered office: Science Park 408, 1098 XH, Amsterdam
- d. Phone: +31 202269700


### b) Amount: **171.000,00 €** (excluding VAT), based on its economic offer of:

- 2.920,00 euros (VAT excluded) Unit price for sequencing and data analysis of tumor genomic DNA and normal blood DNA (reference DNA), including extraction, sequencing, data analysis and reporting of the results in a manner valid for routine diagnostic purposes.
- 500,00 euros (excluding VAT) Unit price for RNA sequencing and reporting from the same piece of tumoral tissue

# c) Other criteria offered:

- Quality control of the samples by shallow sequencing before full whole genome sequencing.
- Allow small batches of samples (minimum of 2 samples per batch) to be sent.
- Turn-around-time of results 15 days or shorter from the reception of the samples.

**Second.-** To notify this award to the beneficiaries of the same as well as to the other bidding companies participating in the bidding procedure.







**Third.-** To publish this award in Perfil del Contratante (web) de la Fundació <a href="http://www.vhir.org">http://www.vhir.org</a>, as well as in the Profile of the Contratación Pública de la Generalitat de Cataluña <a href="https://contractaciopublica.gencat.cat">https://contractaciopublica.gencat.cat</a>.

**Fourth.-** The formalization of these contracts shall be carried out according to the specifications contemplated in Law 9/2017, of November 8, on Public Sector Contracts.

Barcelona, at the date of electronic signature

**CONTRACTING ORGANISM Ms. Montserrat Gimenez Prous** 

Manager

Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR)